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Abstract
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area 
has re-evaluated benzoic acid and alkali benzoates [65-85-0; 532-32-1; 582-25-2] to derive a maximum con-
centration at the workplace (MAK value), considering all toxicity endpoints. Available study reports and pub-
lications are described in detail.
Based on the NOAEC for lung toxicity of 12.6 mg/m3 in a 4-week inhalation study in rats, a MAK value of 
0.5 mg/m3 for the strongly irritating benzoic acid has been derived. Alkali benzoates are only slightly irritating. 
In consideration of the systemic NOAEC of 250 mg/m3 in another 4-week inhalation study in rats exposed to 
benzoic acid, a MAK value for alkali benzoates of 10 mg/m3 (inhalable fraction), calculated as benzoate, has 
been derived. Benzoic acid and alkali benzoates are assigned to Peak Limitation Category II, because systemic 
effects are critical, and excursion factors of 2 for alkali benzoates and of 4 for benzoic acid are set.
In a developmental toxicity study with sodium benzoate in rats, foetotoxic effects were observed at 1850 mg/kg 
body weight and day. The NOAEL was 1340 mg/kg body weight and day. In mice, rabbits and hamsters, no 
developmental toxicity from sodium benzoate was detected in the foetuses of dams treated with up to 175, 250 
or 300 mg/kg body weight and day, respectively. The differences between the NOAEL for rats, mice, rabbits 
and hamsters scaled to an inhalation concentration at the workplace and the MAK value are considered so 
large that damage to the embryo or foetus is unlikely when the MAK value is observed. Therefore, benzoic acid 
and alkali benzoates are classified in Pregnancy Risk Group C.
Benzoic acid and alkali benzoates are not regarded as genotoxic. Long-term studies with sodium benzoate in 
rats and mice were of limited validity and do not point to a carcinogenic potential. Sensitization is not expect-
ed as benzoic acid and alkali benzoates are not contact sensitizers in animal studies. Immediate contact reac-
tions observed in animals and humans are based on a non-immunologic mechanism. Skin contact is expected 
to contribute significantly to the systemic toxicity. Therefore, benzoic acid and alkali benzoates are designated 
with an “H”.
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1) The substance can occur simultaneously as vapour and aerosol.
2) causes pseudoallergic reactions, see Toxikologisch-arbeitsmedizinische Begründung von 
MAK-Werten (21st issue 1995)
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Benzoic acid 0.1 ml/m3 (ppm) ≙ 0.5 mg/m3 R (respirable 
fraction)
Alkali benzoates 10 mg/m3 I (inhalable fraction, as benzoate)
Peak limitation (2016)
Benzoic acid Category II, excursion factor 4
Alkali benzoates Category II, excursion factor 2





Prenatal toxicity (2016) Pregnancy Risk Group C




Chemical name benzoic acid
1) The substance can occur simultaneously as vapour and aerosol.
2) causes pseudoallergic reactions, see Toxikologisch-arbeitsmedizinische Begründung von 
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Molecular formula C7H6O2 (benzoic acid)
C7H5O2Na (sodium benzoate)
C7H5O2K (potassium benzoate)
Molar mass 122.12 g/mol (benzoic acid)
144.11 g/mol (sodium benzoate)
160.21 g/mol (potassium benzoate)
Melting point 122.4 °C (benzoic acid) (OECD 2004)
330.6 °C (sodium benzoate) (OECD 2004)
no data (potassium benzoate)
Boiling point at 1013 hPa 249.2 °C (benzoic acid) (OECD 2004)
464.9 °C (sodium benzoate) (OECD 2004)
no data (potassium benzoate)
Vapour pressure at 25 °C 0.0009 hPa (benzoic acid) (SRC 2014 a)
(vapour saturation concentration 4.4 mg/m3)
< 0.001 hPa (sodium benzoate) (SRC 2014 b)
no data (potassium benzoate)
log KOW3) 1.87 (benzoic acid) (SRC 2014 a)
–2.27 (calculated) (sodium benzoate) (SRC 2014 b)
no data (potassium benzoate)
Solubility at 25 °C 3.4 g/l water (benzoic acid) (SRC 2014 a)
556 g/l water (sodium benzoate) (SRC 2014 b)
no data (potassium benzoate)
pKs value 4.19 (benzoic acid) (OECD 2004)
1 ml/m3 (ppm) ≙ 5.067 mg/m3 1 mg/m3 ≙ 0.197 ml/m3 (ppm)
Stability benzoic acid: anhydride formation at about 150 °C, 
decarboxylation at about 370 °C (ECHA 2011);
sodium and potassium benzoate: no data
3) octanol/water partition coefficient.
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Production benzoic acid: almost exclusively by cobalt-cata-
lyzed liquid-phase air oxidation of toluene (NLM 
2016);
sodium benzoate: neutralization of benzoic acid 
with sodiumbicarbonate, sodium carbonate or 
sodium hydroxide (CIR 2011);
potassium benzoate: reaction of methylbenzo-
ate with potassium thioacetate (CIR 2011)
Purity benzoic acid: > 990 g/kg (pharmaceutical 
quality) (ECHA 2011);
sodium and potassium benzoate: no data
Impurities benzoic acid: according to the German pharma-
copoeia (Deutsches Arzneibuch): cinnamic acid 
max. 0.1%, heavy metals max. 0.001%, ash max. 
0.1%, organic and inorganic chlorides not 
detectable (ECHA 2011);
sodium and potassium benzoate: no data
Uses benzoic acid: production of phenol,  sodium 
benzoate and for the synthesis of other 
substances (OECD 2004), used as a bactericide, 
fungicide and viricide, and for the disinfection 
of materials (ECHA 2011);
sodium and potassium benzoate: as preserva-
tives (OECD 2004)
For benzoic acid there is documentation available from 1986 (documentation “Ben-
zoesäure” 1986, available in German only) and a supplement from 1995 (supple-
ment “Benzoesäure” 1995, available in German only) on its allergenic effects. The 
present supplement is based on new data.
The alkali benzoates have been included in this supplement as in aqueous solution, 
depending on the pH, the benzoates are present in equilibrium with benzoic acid.
1  Toxic Effects and Mode of Action
Benzoic acid is strongly irritating to the eyes and causes irreversible damage to the 
cornea in some cases, whereas it is only mildly irritating to the skin. Sodium benzo-
ate is, at most, slightly irritating to the eyes, and not irritating to the skin. Benzoic 
acid and its salts can induce immediate, non-immunological erythematous or urti-
carial reactions. Urticarial swelling occurs usually within 15 to 30 minutes after the 
exposure, and subsides as a rule after 2 to 3 hours. After oral administration of a 
total of 35 g within 20 days, benzoic acid caused symptoms such as nausea, head-
aches, weakness, burning and irritation in the oesophagus and digestive disorders 
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kidney weights, ataxia, tremor, excitation, aggressive behaviour, convulsions and 
mortality were observed in rats after repeated oral administration of benzoic acid 
or sodium benzoate doses of more than 2000 mg/kg body weight and day. Histo-
pathological changes were diagnosed in the brain, the liver and the kidneys. In a 
4-week inhalation study with rats, benzoic acid caused interstitial inflammation of 
the lungs with subsequent fibrosis at concentrations of 25 mg/m3 and above.
In a study of the toxic effects on prenatal development in Wistar rats, foetotoxic 
effects, such as a reduced number of live foetuses, reduced foetal weights, reduced 
ossification and an increase in the incidences of skeletal, external and internal vari-
ations and malformations, were found, with simultaneous maternal toxicity, at so-
dium benzoate dose levels of about 1850 mg/kg body weight and day and above. In 
prenatal toxicity studies with mice, rabbits and hamsters, no developmental or ma-
ternal toxicity occurred up to the highest doses tested of 175 mg/kg body weight 
(mouse), 250 mg/kg body weight (rabbit) and 300 mg/kg body weight (hamster).
In vitro genotoxicity studies indicate benzoic acid and its salts have clastogenic 
effects at high doses, although in vivo studies yielded negative results for chromo-
somal aberrations in rats.
Long-term studies with rats and mice yielded no evidence of a carcinogenic effect 
of benzoic acid or sodium benzoate.
2  Mechanism of Action
The effect of benzoic acid on the eyes and mucosa is based on its acidity. The sys-
temic toxicity of benzoic acid is similar to that of intoxication with salicylic acid 
(o-hydroxybenzoic acid). For both substances, a similar mechanism is assumed: the 
inhibition of mitochondrial respiration after saturation of the conjugation of gly-
cine and glucuronic acid (ECHA 2011).
In isolated rat hepatocytes, benzoic acid (1 mM) causes the inhibition of urea syn-
thesis by about 50% and leads to an 80% reduction in cellular aspartate concentra-
tions. In isolated mitochondria, benzoic acid (1 mM) was shown to inhibit pyruvate 
carboxylase (Cyr and Tremblay 1989).
Benzoic acid and its salts can induce an immediate, non-immunological response 
or non-immunological contact urticaria, for which no specific IgE antibodies are 
detectable. These reactions, which are to be classified as irritant reactions, already 
occur on first contact, and therefore do not require any previous sensitization 
phase. The reactions are restricted as a rule to the area of contact, and demonstrate 
a clear dependency on the amount or concentration of the active substance (see also 
supplement “Benzoesäure” 1995, available in German only). Prostaglandins or his-
tamine are possibly mediators for the reactions. As regards sensitivity to benzoic 
acid, there are marked differences between animal species (Lahti 1987; Lahti and 
Maibach 1985; Lahti et al. 1983, 1987).
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
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3  Toxicokinetics and Metabolism
3.1  Absorption, distribution, elimination
There are no data available for absorption following inhalation exposure.
After ingestion of benzoic acid or sodium benzoate, absorption is rapid and virtu-
ally complete in humans, rats, dogs and hamsters (ECHA 2011).
In humans, the peak plasma concentrations are reached within 1 to 2 hours after 
ingestion (ECHA 2011).
The rapid absorption of benzoic acid was confirmed in perfusion studies with rat 
colon. It was also shown that absorption is based on diffusion of the undissociated 
molecule and is dependent on the pH (ECHA 2011).
There are a few studies available for percutaneous absorption in various species 
such as the rat, rhesus monkey, dog, pig, guinea pig and humans as well as in vitro 
tests with human and rat skin. The individual studies are shown in Table 1. To sum-
marize, percutaneous absorption in humans in vivo is about 40% in most studies 
(the individual results are in the range of 14% to 42.6%), and for human skin in vitro 
it is in the range of 30% to 70%.
In vitro studies with benzoic acid in aqueous solutions or ethanol/water solutions 
with human and rat skin indicate maximum flux rates of up to 10 to 20 µg/cm2 and 
hour for low benzoic acid concentrations (for example 4 mg/ml) and of up to 
166 ± 59 µg/cm2 and hour for higher concentrations (40 mg/ml) (van de Sandt et al. 
2004; Nielsen and Nielsen 2006; Nielsen et al. 2009; Nielsen and Sørensen 2012).
Similar flow rates can be estimated from an experimental in vivo study with hu-
mans, in which a larger amount of substance was applied: the percentage of benzo-
ic acid absorbed after 24-hour non-occlusive exposure to 2000 µg/cm2 was 13.6%. 
This yields an absorbed amount of 272 µg/cm2 for the 24-hour observation period. 
Assuming for simplicity that the penetration rate is uniform, the average flux is 
11 µg/cm2 and hour (Wester and Maibach 1976). A limiting factor–and this applies 
also for the other studies with humans listed in Table 1–is, however, the fact that the 
course of dermal penetration over time was not investigated. Therefore, the sub-
stance fluxes can be given only in the form of averaged values over extended periods 
of time, and there is a degree of uncertainty, which possibly results in an underesti-
mation of the fluxes.
The elimination of benzoic acid or sodium benzoate (see Section  3.2) with the 
urine in humans, rats, hamsters and dogs, is rapid and virtually complete (94%–
100% over 24 hours; Bridges et al. 1970), especially in the form of metabolites. In 
other species such as ferrets and non-human primates on the other hand, it seems 
to be less effective. Faecal excretion and elimination with the exhaled air appear to 
be minor routes of elimination (ECHA 2011).
Because of the effective elimination in most of the species investigated, no accu-
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3.2  Metabolism
In mammals, the main metabolites of benzoic acid are hippuric acid formed from 
conjugation with glycine, and benzoyl glucuronide resulting from glucuronidation 
(see Figure 1; ECHA 2011).
From the maximum elimination rate, it was calculated that the elimination capac-
ity via glucuronate and glycine conjugation is about 20 g benzoic acid per day in 
humans (ECHA 2011).
The maximum rate of biotransformation of benzoic acid to hippuric acid in hu-
mans is on average 23.0 mg/kg body weight/hour which is close to the maximum 
daily dose of 500 mg/kg body weight (21 mg/kg body weight and hour) recom-
mended for the treatment of hyperammonaemia (see Section 4.2) (ECHA 2011).
In humans, rabbits, rats and pigs, benzoic acid is eliminated almost entirely in the 
form of hippuric acid. In other species, larger amounts of benzoyl glucuronide are 
also eliminated, for example up to 38% in marmosets, 75% in dogs and 20% in fer-
rets (ECHA 2011).
In neonatal rats and rats with protein deficiency, the amount eliminated as hippu-
ric acid was reduced, and about 20% of the radioactively labelled substance in the 
urine was identified as benzoyl glucuronide (ECHA 2011).
As cats are capable of glucuronidation to a limited extent only, they react in a 
particularly sensitive way at and above the concentration that leads to saturation of 
glycine conjugation to hippuric acid (ECHA 2011).
In humans, the most important organs in which the metabolism of benzoic acid 
takes place are the liver and the kidneys. Although the conjugation rate in the renal 
cortex is higher than in the liver, the liver is nevertheless considered to be the quan-
titatively most important organ for glycine conjugation due to its greater mass and 
central anatomical location (ECHA 2011).
Figure 1 Metabolism of benzoic acid in rats and humans (according to ECHA 2011)
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
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In vitro experiments suggest that after percutaneous uptake of benzoic acid a 
small amount is also transformed to hippuric acid in the skin (ECHA 2011).
4  Effects in Humans
4.1  Single exposures
Single oral doses of 1 to 1.5 g benzoic acid produced stomach disorders, nausea 
and vomiting (documentation “Benzoesäure” 1986, available in German only).
Single doses of 2000 to 3000 mg sodium benzoate resulted in nausea, headaches, 
weakness, and burning and irritation of the oesophagus (WHO 2000).
In a person weighing 60 kg, the ingestion of 33 g sodium benzoate caused pallor, 
a weak and irregular pulse, general indisposition, headaches and nausea. Similar 
effects were described also after the intake of 50 g sodium benzoate over a period of 
five hours (Nair 2001).
The induction of an asthmatic reaction after oral provocation with sodium ben-
zoate has been described (for example by Petrus et al. 1996). Oral provocation with 
an undocumented amount of benzoic acid produced an asthmatic reaction, rhinitis 
or urticaria in 47 of 100 asthma patients (Rosenhall and Zetterström 1975; see also 
documentation “Benzoesäure” 1986, available in German only); 86 of these 100 pa-
tients reacted to acetyl salicylic acid.
4.2  Repeated exposure
After daily ingestion of 300 to 400 mg benzoic acid with the diet for up to 62 days, 
no changes in the blood picture, urine composition, nitrogen balance or in well-be-
ing were found in 6 men (WHO 2000).
In humans, daily oral doses of less than 500 mg benzoic acid did not produce any 
symptoms (documentation “Benzoesäure” 1986, available in German only).
An earlier study reports that the daily uptake of up to 1000 mg benzoic acid over 
a period of up to 92 days did not produce adverse effects (WHO 2000).
In a volunteer study, the participants received oral doses of benzoic acid of 
1000 mg per day for 5 days. The dose was increased to 1500, 2000 and 2500 mg/day 
every 5 days. Three of the 12 participants received the complete dose of 35 g within 
20 days. In these volunteers marked symptoms, such as nausea, headaches, weak-
ness, burning and irritation in the oesophagus, and digestive disorders were ob-
served (Nair 2001).
In 9 patients undergoing treatment with penicillin who were given a total dose of 
12 000 mg benzoic acid (divided into 8 doses over 5 days in 8 subjects and 8 doses 
over 14 days in one subject), no adverse effects on blood urea nitrogen or creatinine 
clearance were reported (WHO 2000).
In humans, sodium benzoate is used as a therapeutic for hyperammonaemia (con-
genital disorder of the urea cycle metabolism) and reduces the ammonia by conju-
gating with glycine to form hippuric acid, which is eliminated (BUA 1993). Thera-
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rarely result in clinical signs of toxicity, which are mostly limited to anorexia and 
vomiting, especially after intravenous bolus administration (WHO 2000).
Skin reactions after ingestion
In the case of a patient with recurrent urticarial skin reactions over many years and 
suspected occupational and non-occupational exposure to benzoic acid, oral prov-
ocation with 500 mg sodium benzoate led to a severe reaction, which was evaluated 
by the authors as allergic anaphylactic shock (Pevny et al. 1981). Despite the exten-
sive documentation, the actual cause of this reaction and the previous occupational 
exposure are not clear.
In addition to this, especially in persons with chronic or recurrent urticaria/pru-
rigo and suspected intolerance to food additives, urticarial or pruriginous reactions 
after oral provocation with sodium benzoate have been reported (Asero 2006; 
 Juhlin 1981; Malanin and Kalimo 1989; Michils et  al. 1991; Nettis et  al. 2004; 
 Supramaniam and Warner 1986). After induction by oral provocation with sodium 
benzoate, the (re-)occurrence of nasal symptoms in patients with chronic or recur-
rent rhinitis as the result of a corresponding intolerance (Asero 2001, 2002; Pacor 
et al. 2004) has also been described.
Finally, a “fixed drug eruption” to sodium benzoate has also been reported. A fe-
male patient aged 64 years developed pruritis on her ring finger several days after a 
throat infection. Two days later there was infiltrated erythema on the finger, which 
exacerbated to a pustulous reaction after a further 4 days. During the following 2 
years, similar episodes occurred repeatedly, which the patient attributed to the in-
take of a syrup containing sodium benzoate for the treatment of airway infections. 
In a patch test, the patient produced a 1+ reaction to 5% sodium benzoate in petro-
latum after 2 and 4 days. Approximately 15 hours after oral provocation with 
750 mg benzoic acid in 100 ml water, she reported skin changes on the ring finger 
and in the interdigital region. Two days later a blister had formed on the area of skin 
originally affected (Vilaplana and Romaguera 2003).
Recurrent symptoms of the oral mucosa, similar to those of erythema multiforme 
(for example crust formation or ulcers on the lips, tongue or oral mucosa), and of 
the skin (papulo-maculous changes on the hands and forearms) in 7 and 5 of 7 pa-
tients, respectively, were attributed to intolerance to benzoic acid as a food additive. 
During a benzoic acid and benzoate-free diet adhered to for between 6 and 
30 months, 4 of the 7 patients were free of symptoms, but in the 3 patients who were 
not able to adhere to an exclusion diet one or two recurrent mucosal or skin chang-
es occurred over 12 to 29 months. All 7 patients reacted in the patch tests to 5% 
benzoic acid in petrolatum (no data for time of reaction), 3 also reacted to nickel, 3 
to cinnamon, 1 to local anaesthetics (Cain-Mix) and 1 to rubber (no other data). 
During patch testing, the oral symptoms (no other data) recurred in varying de-
grees of severity in some of them. Herpes simplex viruses or an increased antibody 
titre were not found in any of the patients and, according to the authors, there was 
no evidence that pharmaceuticals, ongoing infections or systemic diseases may 
have been the cause (Lewis et al. 1989).
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
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4.3  Local effects on skin and mucous membranes
(Non-immunological) immediate reactions
Benzoic acid and its salts can induce non-immunological immediate erythematous 
or urticarial reactions. The clinical picture with oedema or infiltrates in the upper 
dermis occurs frequently in combination with itching or burning. Purely erythem-
atous reactions are, however, also possible.
In 3 employees engaged in the dispensing or mixing of sodium benzoate, burning 
and itching or erythematous skin reactions in the area of contact, especially during 
phases of more pronounced sweating, occurred about 15 to 45 minutes after con-
tact with sodium benzoate, with a latency period of months to several years. The 
skin changes were reversible between 15 to 30 minutes and a few hours after the 
end of the exposure. The workers were subjected to patch tests with 0.5% sodium 
benzoate in water (non-occlusive), 0.5% sodium benzoate in saline (20 minutes oc-
clusive) and 10% sodium benzoate in petrolatum (non-occlusive) as well as with 
0.25% benzoic acid in water (non-occlusive) and 5% benzoic acid in petrolatum (20 
minutes occlusive). Only 1 of the 3 reacted to occlusive testing with 0.5% sodium 
benzoate, but all 3 to both benzoic acid preparations. Two of 3 control persons re-
acted to 0.5% sodium benzoate (occlusive) and the other to 10% sodium benzoate; 
all three reacted to 0.25% benzoic acid, but not to 5% benzoic acid (Nethercott et al. 
1984).
Non-immunological immediate reactions of the skin to benzoic acid are more fre-
quently reported in case reports of patients with non-occupational exposure. These 
reports involve, for example, patients with perioral urticarial reactions or cheilitis 
as a result of an assumed intolerance to sodium benzoate in toothpaste (Aguirre 
et al. 1993; Munoz et al. 1996) and children with perioral immediate reactions to 
salad dressing containing benzoic acid (Clemmensen and Hjorth 1982). Some of the 
cases, however, were also evaluated as late reactions to patch testing.
Urticarial reactions to benzoic acid occurred in a 20-minute or 30-minute patch 
test also in 14 of 40 children in one study (Rademaker and Forsyth 1989), and in a 
few of the patients tested extensively as a result of an intolerance to balsam of Peru 
(Forsbeck and Skog 1977), and could be suppressed by previous administration of 
an antihistaminic agent in two cases (Forsbeck and Skog 1977).
Studies of urticarial reactions in various collectives of volunteers or patients are 
summarized in Table 2.
4.4  Allergenic effects
Sensitizing effects on the skin
In the documentation from 1986 (documentation “Benzoesäure” 1986, available in 
German only), merely one case report was cited in which benzoic acid is suspected 
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Recent clinical findings
In view of the relatively frequent non-specific urticarial reactions to free  benzoic 
acid, a 5% preparation of sodium benzoate in petrolatum is recommended for test-
ing by the German Contact Dermatitis Research Group (DKG). The reaction index 
(RI)4) of –0.23 and the positivity ratio (PR)5) of about 91% to 92% (Brasch and Uter 
2011; Schnuch et  al. 2008, 2011), however, indicate that this test preparation is 
problematical.
In a comparative evaluation, only a low number (0.2%) of questionable erythema-
tous reactions to sodium benzoate occurred in 441 patients with a reaction to sodi-
um lauryl sulfate (SLS) tested as an irritant control in the clinics of the Information 
Network of Departments of Dermatology (IVDK). In the 641 patients who did not 
react to SLS there were no erythematous reactions, but 0.2% were evaluated as 1+ 
reactions (Geier et al. 2003 b).
In the available studies, when 5% test preparations of benzoic acid or sodium ben-
zoate were used, usually less than 1% of those tested reacted in collectives of up to 
79 046 patients.
A higher number (about 1.3%) was found in a Dutch study with a collective of 627 
patients tested consecutively with 5% benzoic acid (in petrolatum) from January to 
April 1985 (De Groot et al. 1986).
A higher percentage of reactions (1.9%) was found also to 5% sodium benzoate in 
an earlier multicentric study with 465 patients from 7 French dermatological clin-
ics. Benzoic acid produced a reaction that was evaluated as positive in 2.1% of those 
tested. Reactions occurred especially in elderly patients, and were associated with 
(chronic) dermatitis on the leg in about half of the cases (Meynadier et al. 1982).
In a study of intolerance to cosmetics, the medical history and patch test findings 
from 5202 patients were evaluated. Allergic and irritative contact dermatitis were 
diagnosed in 2567 and 1529 patients, respectively. An intolerance to cosmetics, 
sometimes associated with other causes of the skin symptoms and irrespective of 
the genesis, was found in 606 patients (including 420 of an allergic origin), in 309 of 
which (156 of allergic origin) the symptoms were caused by cosmetics alone. In the 
group with an allergic reaction to cosmetics (probably 63 patients), a positive reac-
tion to benzoic acid was found in one of the tested persons. In addition, there were 
34 reactions in total in the tested patients; the total number of tested patients is 
unclear (Broeckx et al. 1987).
In a Belgian study, 25 (0.3%) positive reactions occurred in the 8521 patients test-
ed between 1985 and 1997 (Goossens et al. 1998).
The evaluation of the patch test results of 2059 patients from 8 clinics of the IVDK 
with the ingredients of a provisional series of preservative agents, revealed four 1+ 
and one 2+ reactions as well as 22 questionable reactions (in total 0.25% and 1.1%, 
respectively) among the 2045 patients tested also with sodium benzoate. In this 
study, the reaction index for the test preparation was only –0.66 (Brasch et al. 1993).
4) The reaction index is defined as the ratio: (a – d – i) / (a + d + i); with: a = number of allergic 
 reactions, d = number of questionable reactions, i = number of irritant reactions (Brasch and 
Henseler 1992).
5) The positivity ratio is defined as the percentage of 1+ reactions out of the total positive reactions 
(Geier et al. 2003 a).
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In the subsequent period between 1990 and 1994, 11 349 of 11 485 patients were 
tested also with sodium benzoate in a series in which preservative agents were in-
vestigated in the 24 clinics of the IVDK at that time; 45 positive reactions and 127 
questionable or irritant reactions occurred. The reaction index was –0.5 (Schnuch 
et al. 1998).
Between 1995 and 2008, 34 631 patients were subjected to patch tests with 11 
preservative agents, including sodium benzoate, in 34 clinics of the IVDK. Positive 
reactions occurred in 0.8% of the patients and questionable, follicular or irritant 
reactions in about 1.3% of the patients. The reaction index (RI) and the positivity 
ratio (PR) were –0.23 and 91.7%, respectively (Brasch and Uter 2011).
Later evaluation of the patch test findings recorded in 51 clinics of the IVDK be-
tween 1996 and 2009 yielded a positive result in 512 cases (0.65%) of the 79 046 
 tested patients. The reaction index was –0.23 and the positivity ratio 92.2%. At 
0.89%, the number of reactions was somewhat higher in men than in women (0.58%, 
both standardized for age and sex). The authors attribute the difference to the high-
er sensitivity of men to irritants (Schnuch et al. 2011).
In the period between 1995 and 1998, 2273 patients were tested in the  Buxtehude 
Dermatological Centre with the balsam of Peru test preparation included in the 
standard series. There were 445 positive reactions. Of these patients, 102 were sub-
sequently tested with 20 potential ingredients of balsam of Peru, including 5% ben-
zoic acid in petrolatum; 20 positive reactions (14× 1+, 5× 2+, 1× 3+) were produced. 
No data for irritant reactions were given (Hausen 2001).
In a multicentre study of patch test reactions from 7 clinics of the Finnish Contact 
Dermatitis Group, the findings obtained between 1994 and 1998 with an extended 
series of dental materials were evaluated. Benzoic acid was tested in one of the clin-
ics (test concentration not specified) and produced a reaction regarded as allergic 
or irritant in 18 and 21 of 417 tested persons, respectively. The authors concluded, 
however, that in the reactions classified as allergic, an irritant cause may have been 
present (Kanerva et al. 2001).
Patch tests with 5% benzoic acid in petrolatum produced a positive reaction in 3 
of 285 patients with perioral symptoms suspected to be of allergic origin, which was 
considered relevant by the authors. However, no reactions to 5% sodium benzoate 
were observed (Torgerson et al. 2007).
The evaluation of patch test findings in 5226 patients with and 14 818 patients 
without atopic eczema documented between 1995 and 1999 in the clinics of the 
IVDK, revealed only slight differences between these collectives, with reactions in 
0.36% and 0.25% of the patients, respectively. Patients with current leg ulcers or 
chronic dermatitis on the leg were not included in this study (Jappe et al. 2003).
A 48-hour patch test with 5% sodium benzoate in 45 bakers with a history of ec-
zema on the hand resulted neither in delayed nor immediate reactions, and only in 
one case in slight erythema (Meding et al. 2003).
Experimental findings
A maximization test carried out with five 48-hour applications of a 2% benzoic acid 
preparation in petrolatum at one-day intervals (occlusive application of 2.5% sodi-
um dodecyl sulfate during this period) did not lead to sensitization in any of the 25 
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day interval in the treatment and one-hour pretreatment with 5% to 10% sodium 
dodecyl sulfate (Nair 2001; Opdyke 1979).
After pretreatment with 5% and 10% dibenzoylperoxide for induction in a maximi-
zation test, 10 volunteers who had reacted to the preparation did not react to chal-
lenge treatment with 5% benzoic acid in petrolatum (Leyden and Kligman 1977).
4.5  Reproductive and developmental toxicity
There are no data available.
4.6  Genotoxicity
There are no data available.
4.7  Carcinogenicity
There are no data available.
5  Animal Experiments and in vitro Studies
5.1  Acute toxicity
5.1.1  Inhalation
After one-hour inhalation exposure of rats to benzoic acid (as vapour), an LC50 of 
more than 26 mg/m3 was reported; there were no deaths (BUA 1993).
In rats, the LC50 for benzoic acid (as dust) after exposure for 4 hours was more 
than 12 200 mg/m3; again there were no deaths (OECD 2004).
In Sprague Dawley rats exposed by inhalation to benzoic acid (as dust) for 6 hours, 
an LC50 of more than 1200 mg/m3 was obtained (ECHA 2011).
5.1.2  Oral administration
For benzoic acid, oral LD50 values of 2565 mg/kg body weight were given for rats 
and of 2250 mg/kg body weight for mice (OECD 2004).
In another study, an LD50 of 3790 mg/kg body weight was obtained after oral ad-
ministration of benzoic acid to male and female Sprague Dawley rats. The symp-
toms were exhaustion and convulsions (Monsanto 1981 c).
In cats, 630 mg benzoic acid/kg body weight was determined to be the lowest let-
hal dose. Neurotoxic effects (aggressiveness, hyperaesthesia), subnormal body tem-
perature and changes in the lungs, liver and kidneys occurred (ECHA 2011).
In the case of sodium benzoate, the oral LD50 for rats was 3140 mg/kg body weight 
and, in another study, 4070 mg/kg body weight (OECD 2004).
The LD50 for potassium benzoate in rats, mice and guinea pigs after oral adminis-
tration was more than 10 000 mg/kg body weight (OECD 2004).
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5.1.3  Dermal application
In rabbits, a dermal LD50 of more than 2000 mg/kg body weight was reported for 
benzoic acid (OECD 2004).
In groups of 5 male and 5 female New Zealand White rabbits, 24-hour occlusive 
application of 5000 mg benzoic acid/kg body weight (moistened with saline) on the 
abraded skin of the back produced neither deaths nor clinical signs. The LD50 is 
therefore greater than 5000 mg/kg body weight. At necropsy, pale kidneys were 
found in one animal (Monsanto 1981 d).
In another study with rabbits, a dermal LD50 of more than 10 000 mg benzoic acid/
kg body weight was determined (ECHA 2011).
5.1.4  Intraperitoneal and intravenous injection
The LD50 for benzoic acid in mice was 1460 mg/kg body weight after intraperitoneal 
injection, and that for sodium benzoate in rats after intravenous administration was 
1714 mg/kg body weight (ECHA 2011).
5.2  Subacute, subchronic and chronic toxicity
5.2.1  Inhalation
In a 4-week inhalation study with rats (see Table 3), benzoic acid caused interstitial 
inflammation and fibrosis of the lungs even at the lowest concentration  investigated 
of 25 mg/m3; the effects increased in intensity in a concentration-dependent man-
ner (see Table 4). In the animals exposed to 250 mg/m3 and more, a red nasal dis-
charge was observed. This concentration was the systemic NOAEC (no observed 
adverse effect concentration) (Velsicol Chemical Company 1981).
In a study carried out according to OECD Test Guideline 412, a NOAEC of 
12.6 mg benzoic acid/m3 was obtained. In the respiratory tract, at this concentra-
tion the incidences were only low and statistically not significant, and the severity 
of the findings obtained was only minimal to slight (see Table 3) (The Personal Care 
Products Council 2010). In this study, the aerosol is not characterized in detail. It 
can nevertheless be used for the evaluation, as the results appear plausible when 
both inhalation studies are considered together.
From the two 4-week inhalation studies with benzoic acid in rats, a NOAEC for 
local effects of 12.6 mg/m3 is obtained. Interstitial inflammation and fibrosis oc-
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5.2.2  Oral administration
The studies of the toxicity of benzoic acid and sodium benzoate after oral adminis-
tration are shown in Table 5. As many of the earlier studies have a limited scope and 
insufficient documentation, they can be included in the evaluation only with reser-
vations.
In rats, after oral administration of benzoic acid or sodium benzoate for between 
10 days and 2 years, the NOAELs (no observed adverse effect levels) are within the 
range of about 500 to 1000 mg/kg body weight and day. At the LOAEL (lowest ob-
served adverse effect level), the effects observed included reduced body weight 
gains, increased liver and kidney weights, ataxia, tremor, excitation, aggressive be-
haviour, convulsions and deaths. Histopathological changes were found in the 
brain, the liver and the kidneys (see Table 5).
One study provided evidence of increased anxiety and motor impairment in rats 
after oral administration of 200 mg sodium benzoate/kg body weight and day for 
4 weeks (Noorafshan et al. 2014). As only one dose was investigated, it is not possi-
ble to assess whether the effects were actually substance-related.
In mice, NOAELs of about 4160 and 3000 mg/kg body weight and day were ob-
tained after oral administration of sodium benzoate for 10 and 35 days, respectively. 
In the 10-day study, increased enzyme activity was observed in the serum at about 
5000 mg/kg body weight and day and above, and at dose levels of about 6000 mg/kg 
body weight and day and above, irritability, convulsions and increased liver weights 
were found. In addition, in the males, enlarged, necrotic hepatocytes with vacu-
olization were observed, and in the females, mortality occurred (Fujitani 1993). Re-
duced body weights and increased mortality were found also in the 35-day study at 
about 6000 mg/kg body weight and day and above (Toth 1984). In a lifetime study, 
the NOAEL in mice was about 2400 mg/kg body weight and day after the ingestion 
of sodium benzoate with the drinking water for about 2.5 years (Toth 1984). In view 
of the limited study design and shortcomings in the documentation, other studies 
with mice, in which benzoic acid was administered for 3 or 17 months, cannot be 
included in the evaluation.
Cats were the most sensitive species with a NOAEL of 200 mg benzoic acid/kg 
body weight and day. Mortality occurred even at doses of 340 mg/kg body weight 
and day (Bedford and Clarke 1972). As their sensitivity is due to metabolic peculiar-
ities (see Section 3.2), studies with cats are not used for the evaluation.
5.2.3  Dermal application
Benzoic acid doses of 0, 100, 500 or 2500 mg/kg body weight and day were applied 
to the skin of 8 New Zealand White rabbits per group on 5 days a week for 3 weeks. 
No effects were found up to the highest dose tested, so that the NOAEL in this study 
was 2500 mg/kg body weight and day. No details of the type of application and the 
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5.3  Local effects on skin and mucous membranes
5.3.1  Skin
The available studies of the irritant effects of benzoic acid and sodium benzoate on 
the skin are summarized in Table 6.
On the skin of rabbits, benzoic acid was found to be non-irritating or only mini-
mally irritating in several studies (BUA 1993; ECHA 2011; Monsanto 1981 b).
In two studies, sodium benzoate was found to be non-irritating on the skin of 
rabbits (ECHA 2011). No other data are available for the studies.
In a test for non-immunological reactions with guinea pigs, marked reactions of 
the ears occurred in an ear swelling test about 30 to 40 minutes after non-occlusive 
application of 20% benzoic acid in ethanol, but not when testing was carried out on 
the animals’ back, abdomen or flanks. The effects of preparations containing 0.2%, 
1% and 5% benzoic acid were less severe and concentration-dependent (Lahti and 
Maibach 1984). Rats and mice, unlike guinea pigs, were found to have no or only 
very slight sensitivity to 20% benzoic acid (Lahti and Maibach 1985).
5.3.2  Eyes
The available studies for the irritating effects of benzoic acid and sodium benzoate 
in the eye are summarized in Table 7.
In most of the studies, benzoic acid was shown to be highly irritating to the eyes 
of rabbits (ECHA 2011). In several studies, damage to the cornea occurred which in 
some cases was irreversible (BUA 1993; ECHA 2011; Monsanto 1981 a, 1983).
In one study, sodium benzoate was not found to be irritating to the rabbit eye 
(ECHA 2011), whereas slight irritation of the eye was reported in another study 
(ECHA 2011).
5.4  Allergenic effects
In experimental studies with benzoic acid, negative results were obtained in the local 
lymph node assay with CBA/J mice using 5%, 10% or 20% benzoic acid in acetone 
(Gerberick et al. 1992), in the Buehler test with 20% benzoic acid in water (Gad et al. 
1986) and with undiluted benzoic acid (ECHA 2011) and in the Draize test (no other 
data; OECD 2004). Negative results were likewise obtained in a maximization test 
with Hartley guinea pigs with 10% (intradermal induction) and 20% (topical induc-
tion and challenge) benzoic acid (Gad et al. 1986) and a mouse ear swelling test with 
CF-1 mice with 20% benzoic acid (induction and challenge) (Gad et al. 1986).
Benzoic acid was also investigated in vitro in a screening test in cultures of he-
pa1C1C7 mouse hepatoma cells by determining the luciferase activity after activation 
of the antioxidant response element without metabolic activation (KeratinoSens As-
say) and in a modified procedure for recognizing potential prohaptens by adding an S9 
fraction from Aroclor-induced rat liver. The results of both tests were negative (Natsch 
and Emter 2008; Natsch and Haupt 2013). Likewise, a similar in vitro experiment with 
a human skin cell line (HaCaT) and studies of chemical reactivity determined by 
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5.5  Reproductive and developmental toxicity
5.5.1  Fertility
In a 4-generation study with rats, groups of 20 male and 20 female animals were 
given benzoic acid doses of 5000 or 10 000 mg/kg diet (about 450 or 900 mg/kg 
body weight and day, conversion factor 0.09 according to EFSA (2012); see also 
 Section 5.2.2). No adverse effects on reproduction (sterility, delayed sexual maturi-
ty, litter size, total number of offspring, survival of the offspring) and no toxic effects 
on the parents or offspring (clinical observations, body weights, organ weights, his-
topathological examination) were found (Kieckebusch and Lang 1960). Due to 
shortcomings in the study design and documentation, the usefulness of this study 
is limited.
The results of a dominant lethal test in male rats given oral doses of sodium ben-
zoate of up to 5000 mg/kg body weight as a single dose or repeat doses on 5 days, 
were negative (FAS 1974).
Benzoic acid was not found to be uterotrophic in rats and mice and inactive in a 
human oestrogen receptor (expression of ERα) yeast oestrogenicity assay (Ashby 
et al. 1997).
5.5.2  Developmental toxicity
Studies of the developmental toxicity of benzoic acid and sodium benzoate are 
shown in Table 8.
In Wistar rats, gavage administration of 510 mg benzoic acid/kg body weight on 
gestation day 9 had no effects in either the dams or the foetuses (Kimmel et  al. 
1971). In the same strain, gavage administration of doses of 25 mg/kg body weight 
and day and more from gestation days 6 to 15 resulted in increased resorptions 
(Nair 2001). It is not specified whether these were early or late resorptions. This is 
also the case in a study by the same research group with hamsters, in which in-
creased resorptions were found at dose levels of 30 mg/kg body weight and day and 
above (Nair 2001).
In a feeding study of the toxic effects on prenatal development in Wistar rats given 
sodium benzoate from gestation days 1 to 20, foetotoxic effects such as a reduced 
number of live foetuses, reduced foetal weights, reduced ossification and increased 
incidences of skeletal, external and internal variations and malformations were 
found at about 1850 mg/kg body weight and day and above. At the same time, food 
consumption and body weight gains were reduced in the dams. The NOAEL for 
developmental and maternal toxicity was about 1340 mg sodium benzoate/kg body 
weight and day (BUA 1993; Onodera et al. 1978).
In studies of the toxic effects on prenatal development with rats, mice, rabbits and 
hamsters, no developmental or maternal toxicity occurred in any of these animals 
up to the highest sodium benzoate doses tested of 175 mg/kg body weight (rat, 
mouse), 250 mg/kg body weight (rabbits) and 300 mg/kg body weight (hamster) 
(FDA 1972).
Two studies with intraperitoneal administration of sodium benzoate (Minor and 
Becker 1971) are not included in the evaluation, as direct effects on the embryos 
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In a feeding study with sodium benzoate in Wistar rats from gestation days 1 to 20 
and examination of the animals up to postnatal day 56, eye opening was delayed in 
the offspring at about 1340 mg/kg body weight and day and above. The NOAEL for 
postnatal development was about 670 mg/kg body weight and day. At about 
1850 mg/kg body weight and day and above, food consumption, body weight gains 
and survival were reduced in the dams. The NOAEL for maternal toxicity was about 
1340 mg/kg body weight and day (BUA 1993; Onodera et al. 1978).
A study with prenatal and postnatal administration of sodium benzoate to Wistar 
rats, did not yield maternal or foetotoxicity up to the high dose of about 900 mg/kg 
body weight and day (Crane and Lachance 1985).
In Sprague Dawley rats, sodium benzoate doses of about 450 mg/kg body weight 
and day administered with the diet from weaning up to mating and during the en-
tire gestation period led to reduced food consumption and an increase in liver en-
zyme activities in the dams. The NOAEL was about 90 mg/kg body weight and day. 
Changes in the body weights of the offspring were not dose-dependent. Therefore, 
a NOAEL for toxic effects on postnatal development of about 450 mg/kg body 
weight and day was obtained (Mowafy et al. 2001).
5.6  Genotoxicity
5.6.1  In vitro
Data for the in vitro genotoxicity of benzoic acid and alkali benzoates are given in 
Table 9.
In several tests for differential killing with Bacillus subtilis, positive and negative 
results were obtained with benzoic acid or the alkali salts. Data for cytotoxicity are 
lacking in all studies, one study is available only as an abstract, some studies are 
poorly documented.
In several tests for induction of the SOS response in Escherichia coli and Salmo-
nella typhimurium as well as in a large number of bacterial mutagenicity tests with 
and without the addition of metabolic activation, however, only negative results 
were obtained (see Table 9).
In the comet assay with human lymphocytes, DNA strand breaks were induced in 
one study with benzoic acid only at the highest concentration tested of 5 mM and 
in another study at concentrations of 0.4 mM and above (Demir et al. 2010; Yilmaz 
et al. 2014). Data for cytotoxicity are not available in either study.
Another comet assay yielded positive results for sodium benzoate at the  lowest 
concentration tested of 6.25 µg/ml (0.04 mM) and above, whereas the results were 
negative for potassium benzoate up to the highest concentration tested of 
1000 µg/ml (Zengin et al. 2011). Data for cytotoxicity are not available.
In several studies with benzoic acid or sodium benzoate, the incidences of sister 
chromatid exchange were not significantly increased in human and hamster cells 
whereas an increase in the incidence of sister chromatid exchange occurred at con-
centrations of 2 mM and above in a study with sodium benzoate in hamster cells 
(Abe and Sasaki 1977). An increase was likewise found at 0.4 mM benzoic acid and 
above in a study with human lymphocytes (Yilmaz et al. 2009). In studies with hu-
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at high concentrations of 8 or 10 mM sodium benzoate (Mpountoukas et al. 2008; 
Xing and Zhang 1990). In other studies with sodium benzoate and potassium ben-
zoate, increased incidences of sister chromatid exchange were found at 6.25 and 
62.5 µg/ml (0.04 and 0.4 mM) and above, respectively; however, compared with the 
increase in the positive control group (0.2 µg mitomycin C/ml: 10.2-fold increase 
compared with the incidence in controls) the increase was only slight (sodium ben-
zoate: 2.6-fold increase at 100 µg/ml compared with the incidence in controls ; po-
tassium benzoate: 2.2-fold increase at 1000 µg/ml compared with the incidence in 
controls) (Zengin et al. 2011).
In the concentration range up to 0.1 mg/ml (0.8 mM), benzoic acid did not induce 
chromosomal aberrations in CHL cells (a cell line derived from Chinese hamster 
lung) (ECHA 2011), whereas no unequivocal results were obtained in the higher 
concentration range at 1 mg/ml (8.2 mM) and above (Ishidate 1988; Ishidate et al. 
1984, 1988). An increase was found at concentrations of 0.4 mM benzoic acid and 
above in a study with human lymphocytes (Yilmaz et al. 2009).
Negative results were obtained for sodium benzoate in concentrations of up to 
0.2 mg/ml (1.4 mM) in a chromosomal aberration test with a human embryonal 
lung cell line (WI-38) (FDA 1974).
In four other studies, an increase in chromosomal aberrations was induced by 
 sodium benzoate in hamster cells, in one study at concentrations of 2 mM and 
above. The mitotic index was not reduced up to 10 mM (Abe and Sasaki 1977; 
 Ishidate et al. 1988). In another study, a positive result was found for sodium benzo-
ate only at the high concentration of 2 mg/ml (13.9 mM); data for cytotoxicity were 
not given (Ishidate 1988; Ishidate and Odashima 1977; Ishidate et al. 1984, 1988). 
The two other studies which reported positive results are poorly documented; for 
example, no data was given for the concentrations tested and for cytotoxicity (Ishi-
date and Yoshikawa 1980; Kawachi et al. 1980).
In human lymphocytes, the incidence of chromosomal aberrations was increased 
at sodium benzoate concentrations of 6.25 µg/ml (0.04 mM) and above and at po-
tassium benzoate concentrations of 62.5 µg/ml (0.4 mM) and above (Zengin et al. 
2011). The authors reported that the pH of the medium was unchanged.
In a micronucleus test in human lymphocytes without metabolic activation, mi-
cronuclei were induced by benzoic acid concentrations of 1.6 mM and above 
 (Yilmaz et al. 2009), by sodium benzoate concentrations of 25 µg/ml (0.17 mM) and 
above, and by potassium benzoate concentrations of 125 µg/ml (0.8 mM) and above 
(Zengin et al. 2011). These concentrations had led to a significantly reduced mitotic 
index. The authors reported that the pH of the medium was unchanged.
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5.6.2  In vivo
The data for the in vivo genotoxicity of benzoic acid and sodium benzoate are given 
in Table 10.
In a wing mosaic test with Drosophila melanogaster, a positive result was obtained 
with benzoic acid only at the highest concentration tested of 50 mM. The lower 
concentrations produced negative or equivocal results. The effect of the test sub-
stance was less pronounced than that of the positive control (1 mM EMS) (Demir 
et al. 2008).
Host mediated assays with sodium benzoate are available in which male ICR mice 
were treated once or on 5 days with up to 5000 mg/kg body weight by gavage. The 
mutation frequency was not increased (FDA 1974).
Male ddY mice received single oral doses of benzoic acid or sodium benzoate. 
After 3 and 24 hours, cells from eight different organs were investigated using the 
comet assay. In all cases, no DNA strand breaks were induced (Sasaki et al. 2002).
A chromosomal aberration test in the bone marrow of male rats given single oral 
doses or five daily oral doses of up to 5000 mg sodium benzoate/kg body weight 
yielded negative results (FDA 1974).
In a poorly documented study which is available only in the form of a table, a neg-
ative result was reported in the chromosomal aberration test with sodium benzoate 
in rats (Kawachi et al. 1980).
In a dominant lethal test, male rats received single oral doses or daily oral doses 
on five days of up to 5000 mg sodium benzoate/kg body weight. In comparison with 
the study controls and the historical controls, no dominant lethal mutations were 
induced (FDA 1974).
Summary:
Benzoic acid and sodium benzoate are not mutagenic in the Salmonella mutagenic-
ity test in vitro. The clastogenic effects in mammalian cells found in vitro were not 
confirmed in vivo in tests for chromosomal aberrations in rats. Likewise, in the host 
mediated assay and comet assay in mice, and the dominant lethal test in rats, ben-
zoic acid and sodium benzoate were not genotoxic.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
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5.7  Carcinogenicity
In a carcinogenicity study (see also Section 5.2.2), groups of 50 male and 52 female 
F344 rats were given sodium benzoate (purity: not specified) for 18 to 24 months 
with the diet in concentrations of 0%, 1% or 2% (about 0, 500 or 1000 mg/kg body 
weight and day, conversion factor 0.05 according to EFSA 2012). The control groups 
consisted of 25 male and 43 female animals. The food consumption was controlled 
to prevent any excesses; the drinking water was available ad libitum. Due to inter-
current infections (mycoplasms and sialodacryoadenitis virus), the survival in sev-
eral groups was very low. All surviving animals were killed after 18 to 25 months 
and examined. There were no unusual clinical effects, and only slight differences in 
mean body weights and mortality between the treated animals and the control 
groups were found. The tumours observed in the treated animals were not signifi-
cantly different from those found in the controls as regards type, incidence and time 
to occurrence (Sodemoto and Enomoto 1980). Due to the infection-related, low 
survival in several groups and the limited documentation, the usefulness of the 
study for the evaluation is also only limited.
In a lifetime study, groups of 50 male and 50 female Swiss mice were given 2% 
sodium benzoate (purity: 99%) with the drinking water (see also Section 5.2.2). 
The control group consisted of 100 male and 100 female animals. Clinical observa-
tions and the determination of body weights as well as gross-pathological and his-
topathological examinations were carried out (liver, spleen, kidneys, bladder, thy-
roid gland, heart, pancreas, testes, ovaries, brain, nasal turbinates, at least four 
pulmonary lobes and all conspicuous organs) in all animals. The average daily in-
take of sodium benzoate was 1800 mg/kg body weight and day (conversion factor 
0.09 according to EFSA 2012). No treatment-related effects on survival or tumour 
incidences could be found (Toth 1984). In view of the sufficiently high number of 
animals and the detailed histopathological examination, this study is considered to 
be of relevance (OECD 2004). However, the study is to be criticized due to the fact 
that only one dose was tested.
5.8  Other effects
In rabbits, daily intravenous injections of sodium benzoate (40 mg/kg body weight) 
resulted in damage to the retina within three days. Histopathological examination 
revealed exudative detachment of the retinal neuroepithelium from the pigment 
epithelium. The toxic effect was especially noticeable in the layer of the rod and 
cone cells (Grant and Schuman 1993).
6  Manifesto (MAK value/classification)
The critical effects of benzoic acid are the strong irritation of the eyes and the pul-
monary toxicity after inhalation exposure. In the case of alkali benzoates, systemic 
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MAK value. No suitable data with humans are available for the derivation of a 
MAK value.
As regards the alkali benzoates, which are at best slightly irritating to the eyes, the 
systemic toxicity is the main effect, so that the MAK value can be derived from this. 
After repeated ingestion of benzoic acid or sodium benzoate by rats, relatively high 
NOAELs in the range of 500 to 1000 mg/kg body weight are obtained. The following 
toxicokinetic data are taken into consideration for the extrapolation of the NOAEL 
of 500 mg/kg body weight to a concentration in workplace air: the daily exposure of 
the animals in comparison with the 5 days per week exposure at the workplace (7:5), 
the corresponding species-specific correction value (1:4) for the rat, the oral absorp-
tion (100%, see Section 3.1), the body weight (70 kg) and respiratory volume (10 m3) 
of the person, and the assumed 100% absorption by inhalation. The concentration 
calculated from this is 1225 mg/m3. However, the systemic NOAEC of 250 mg ben-
zoic acid/m3 resulting from the 4-week inhalation study with rats (Velsicol Chemical 
Company 1981) is lower, so that the MAK value is derived from this. Assuming an 
increase in effects over time from the short-term study (1:6), the increased respira-
tory volume at the workplace (1:2) and the extrapolation of the data from experi-
mental studies with animals to humans (1:2), a MAK value of 10 mg/m3 I (inhalable 
fraction, as benzoate) has been established for alkali benzoates.
For the strongly irritating benzoic acid, the MAK value is derived on the basis of 
its local effects. In the 4-week inhalation study with rats (Velsicol Chemical Com-
pany 1981), benzoic acid caused local pulmonary toxicity in the form of interstitial 
inflammation and fibrosis at concentrations of 25 mg/m3 and above. From another 
4-week inhalation study with benzoic acid in rats, a NOAEC of 12.6 mg/m3 for  local 
pulmonary toxicity was calculated (The Personal Care Products Council 2010). As-
suming an increase in effects over time from the short-term study (1:6), the in-
creased respiratory volume at the workplace (1:2) and the extrapolation of the data 
from experimental studies with animals to humans (1:2), the MAK value is derived 
from this NOAEC of 12.6 mg/m3. As the vapour saturation concentration of benzo-
ic acid is about 4.4 mg/m3, at this MAK value the substance can be present in va-
pour form, and the MAK value is given in ml/m3. For benzoic acid, therefore, a 
MAK value of 0.1 ml/m3 has been established. This value corresponds to 0.5 mg/m3 
for the R (respirable) fraction, as the lungs are the target organ.
Peak limitation. As far as the alkali benzoates are concerned, the systemic tox-
icity is the main effect. They are therefore classified in Peak Limitation Category II 
with the standard excursion factor of 2, as no data for their half-lives are available.
As the interstitial inflammation in the lungs with fibrosis is the critical effect for 
determining the threshold limit value and this effect does not occur immediately, 
but requires a longer exposure period before it manifests itself, benzoic acid is 
classified in Peak Limitation Category II. As in the 4-week inhalation study with rats 
no irritation occurred at a concentration of 12.6 mg benzoic acid/m3, an excursion 
factor of 4 can be set.
Prenatal toxicity. In a study of the toxic effects on prenatal development in  Wistar 
rats, foetotoxic effects such as a reduced number of live foetuses, reduced foetal 
weights, reduced ossification and increased incidences of skeletal, external and inter-
nal variations and malformations were found at dose levels of about 1850 mg sodium 
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benzoate/kg body weight and day and above. At the same time, food consumption 
and body weight gains were reduced in the dams. The NOAEL for developmental and 
maternal toxicity is about 1340 mg sodium benzoate/kg body weight and day (BUA 
1993; Onodera et al. 1978). In studies of the toxic effects on prenatal development 
with mice, rabbits and hamsters, no developmental or maternal toxicity occurred up 
to the highest doses tested of 175 mg/kg body weight (mouse), 250 mg/kg body 
weight (rabbit) and 300 mg/kg body weight (hamster) (FDA 1972). As these were the 
highest doses in each case, the true NAEL (no adverse effect level) is higher. In a study 
with prenatal and postnatal administration to Wistar rats, no maternal toxicity or 
foetotoxicity was found up to the highest dose tested of about 900 mg/kg body weight 
and day (Crane and Lachance 1985). The following toxicokinetic data are taken into 
consideration for the extrapolation of the NOAELs of about 1340 mg/kg body weight 
and day for rats, of 175 mg/kg body weight and day for mice, of 250 mg/kg body 
weight and day for rabbits and of 300 mg/kg body weight and day for hamsters to a 
concentration in workplace air: the corresponding species-specific correction values 
for the rat, the mouse, the rabbit and the hamster (1:4; 1:7; 1:2.4; 1:5.5), the demon-
strated oral absorption (100%), the body weight (70 kg) and respiratory volume 
(10 m3) of the person, and the assumed 100% absorption by inhalation. The concen-
trations calculated from this are 2345, 175, 730, and 382 mg/m3 air (corresponding to 
1970, 147, 613, and 321 mg/m3 air for the benzoate), respectively. The differences 
between these values and the MAK value of 10 mg/m3 are thus 197-fold (rat), 14-fold 
(mouse), 61-fold (rabbit) and 32-fold (hamster), respectively. As the differences be-
tween these values and the MAK value of 10 mg/m3 are sufficiently large, sodium 
benzoate is classified in Pregnancy Risk Group C. This applies also to other alkali 
benzoates, as the effect is not mediated by the alkali content.
For benzoic acid, only three studies are available (Kimmel et al. 1971; Nair 2001). 
These were not carried out according to valid guidelines and have serious short-
comings, such as the use of only one dose and treatment on only one gestation day 
or the lack of information about early or late resorptions. The systemic effects of 
benzoic acid, however, are expected to be similar to those of its salts, as these effects 
are most likely mediated via the benzoate formed endogenously. In addition, the 
MAK value for benzoic acid of 0.5 mg/m3 is lower than that for the benzoates, so 
that the difference between this and the NOAEL for the developmental toxicity of 
the benzoate is greater by a factor of 20. In view of this greater difference, benzoic 
acid is likewise classified in Pregnancy Risk Group C.
Carcinogenicity. Benzoic acid and its alkali salts are not genotoxic. Because of 
various shortcomings, the available long-term studies with sodium benzoate in rats 
and mice can only be used for the evaluation to a limited extent. Nevertheless, there 
is no evidence of carcinogenic effects in the studies. Benzoic acid and its alkali salts 
are therefore not classified in one of the categories for carcinogens.
Germ cell mutagenicity. In the Salmonella mutagenicity test, benzoic acid was 
not mutagenic in vitro. The clastogenic effects found in vitro were not confirmed in 
tests for chromosomal aberrations in vivo in rats. In the dominant lethal test with 
rats, benzoic acid was not genotoxic in germ cells. There is thus no evidence of germ 
cell mutagenicity, so that benzoic acid and its alkali salts are not classified in one of 
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Absorption through the skin. Studies of absorption through the skin are avail-
able only for benzoic acid. As benzoic acid dissolved in aqueous media is present in 
equilibrium with its dissociated form (benzoate), the two compounds cannot be 
differentiated with regard to absorption through the skin; dermal absorption takes 
place via the undissociated form. Assuming a maximum absorption rate of 
166 µg/cm2 and hour (Nielsen and Sørensen 2012), about 332 mg benzoic acid 
would be absorbed through the skin under standard conditions (2000 cm2, 1-hour 
exposure). The NOAEC for systemic effects after short-term inhalation exposure in 
rats is 250 mg/m3, so that after extrapolation to long-term exposure (1:6), extrapo-
lation to humans (250 mg/m3 × 10 m3 respiratory volume per 8-hour exposure) and 
after halving the dose because the results were obtained on the basis of animal ex-
periments, (see List of MAK and BAT Values, Section I) and correction for the in-
creased respiratory volume at the workplace (1:2), a systemically tolerable amount 
of 104 mg is obtained. The possible contribution of absorption through the skin to 
systemic toxicity is therefore not negligible, so that both benzoic acid and alkali 
benzoates are designated with an “H” (for substances which can be absorbed 
through the skin in toxicologically relevant amounts).
Sensitization. Although in numerous clinical epidemiological studies patch test 
reactions to sodium benzoate have been reported, these are almost always only 
weakly positive and are to be regarded as possibly irritant reactions and thus as 
falsely positive. The results from animal experiments for contact sensitization are 
all negative, and the immediate reactions to benzoic acid and sodium benzoate 
found in humans and guinea pigs are to be regarded as non-immunological reac-
tions. Therefore, in view of the findings detailed in this supplement, there is still no 
necessity for designating the substance with “Sh” (for substances which cause sen-
sitization of the skin). As no findings are available for respiratory sensitization, ben-
zoic acid and alkali benzoates are not designated with “Sa” (for substances which 
cause sensitization of the airways).
7 References
Abe S, Sasaki M (1977) Chromosome Aberrations and Sister Chromatid Exchanges in Chinese 
Hamster Cells Exposed to Various Chemicals. J Natl Cancer Inst 58: 1635–1641
Ackermann K, Lombardi Borgia S, Korting HC, Mewes KR, Schäfer-Korting M (2010) The Phe-
nion® full-thickness skin model for percutaneous absorption testing. Skin Pharmacol Physiol 
23: 105–112
Adams TB, Cohen SM, Doull J, Feron VJ, Goodman JI, Marnett LJ, Munro IC, Portoghese PS, 
Smith RL, Waddell WJ, Wagner BM (2005) The FEMA GRAS assessment of benzyl deriva-
tives used as flavor ingredients. Food Chem Toxicol 43: 1207–1240
Aguirre A, Izu R, Gardeazabal J, Díaz-Pérez JL (1993) Edematous allergic contact cheilitis from 
a toothpaste. Contact Dermatitis 28: 42
Aktac T, Kaboglu A, Ertan F, Ekinci F, Huseyinova G (2003) The effects of citric acid (antioxidant) 
and benzoic acid (antimicrobial agent) on the mouse liver: biochemical and histopathological 
study. Biologia 58: 343–347
Andersen KE, Maibach HI, Anjo MD (1980) The guinea-pig: an animal model for human skin 
absorption of hydrocortisone, testosterone and benzoic acid. Br J Dermatol 102: 447–453
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
Benzoic acid and alkali benzoates 1821
Anderson D, Styles JA (1978) The bacterial mutation test. Appendix II. Br J Cancer 37: 924–930
Asero R (2001) Perennial rhinitis induced by benzoate intolerance. J Allergy Clin Immunol 107: 
197
Asero R (2002) Food additives intolerance: a possible cause of perennial rhinitis. J Allergy Clin 
Immunol 110: 937–938
Asero R (2006) Sodium benzoate-induced pruritus. Allergy 61: 1240–1241
Ashby J, Lefevre PA, Odum J, Tinwell H, Kennedy SJ, Beresford N, Sumpter JP (1997) Failure to 
confirm estrogenic activity for benzoic acid and clofibrate: implications for lists of endo-
crine-disrupting agents. Regul Toxicol Pharmacol 26: 96–101
Basketter DA, Wilhelm KP (1996) Studies on non-immune immediate contact reactions in an 
unselected population. Contact Dermatitis 35: 237–240
Bayer AG (1986) Benzoesäure DAB 8, Prüfung auf reizende/ätzende Wirkung am Kaninchenauge, 
Studiennummer: T 9021448 (German), Bayer AG, Wuppertal, unpublished report
Bedford B, Clarke MA (1972) Experimental benzoic acid poisoning in the cat. Vet Rec 90: 53–58
Brasch J, Henseler T (1992) The reaction index: a parameter to assess the quality of patch test 
preparations. Contact Dermatitis 27: 203–204
Brasch J, Uter W (2011) Characteristics of patch test reactions to common preservatives incor-
porated in petrolatum and water, respectively. Contact Dermatitis 64: 43–48
Brasch J, Henseler T, Frosch PJ (1993) Patch test reactions to a preliminary preservative series 
– a retrospective study based on data collected by the Information Network of Dermatologi-
cal Clinics (IVDK) in Germany. Derm Beruf Umwelt 41: 71–76
Bridges JW, French MR, Smith RL, Williams RT (1970) The fate of benzoic acid in various spe-
cies. Biochem J 118: 47–51
Broeckx W, Blondeel A, Dooms-Goossens A, Achten G (1987) Cosmetic intolerance. Contact 
Dermatitis 16: 189–194
Bronaugh RL, Stewart RF, Congdon ER, Giles Jr AL (1982) Methods for in vitro percutaneous 
absorption studies, I. Comparison with in vivo results. Toxicol Appl Pharmacol 62: 474–480
BUA (Beratergremium für umweltrelevante Altstoffe der Gesellschaft Deutscher Chemiker) 
(GDCh-Advisory Committee on Existing Chemicals of Environmental Relevance) (1993) 
Benzoic acid / Sodium benzoate, BUA Report 145, Hirzel, Stuttgart
Bucks DAW, Hinz RS, Sarason R, Maibach HI, Guy RH (1990) In vivo percutaneous absorption 
of chemicals: a multiple dose study in rhesus monkeys. Food Chem Toxicol 28: 129–132
Carver MP, Riviere JE (1989) Percutaneous absorption and excretion of xenobiotics after topical 
and intravenous administration to pigs. Fundam Appl Toxicol 13: 714–722
CIR (Cosmetic Ingredient Review) (2011) Benzyl alcohol, and benzoic acid and its salts and 
benzyl ester, amended final safety assessment, Washington, DC, USA
Clemmensen O, Hjorth N (1982) Perioral contact urticaria from sorbic acid and benzoic acid in 
a salad dressing. Contact Dermatitis 8: 1–6
Coverly J, Peters L, Whittle E, Basketter DA (1998) Susceptibility to skin stinging, non-immuno-
logic contact urticaria and acute skin irritation; is there a relationship? Contact Dermatitis 38: 
90–95
Crane SC, Lachance PA (1985) The effect of chronic sodium benzoate consumption on brain 
monamines and spontaneous activity in rats. Nutr Rep Int 32: 169–177
Cyr DM, Tremblay GC (1989) Potentiation of benzoate toxicity by glyoxylate: Inhibition of pyru-
vate carboxylase and the urea cycle. Biochem Pharmacol 38: 2919–2923
De Groot AC, Weyland JW, Bos JD, Jagtman BA (1986) Contact allergy to preservatives (I). Con-





produktionstitel: BAT Value Documentations 2017
<kurztitel>: Addendum to Methyl bromide 
DOI_Umbruchversand: xxxx
The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 4
Demir E, Kocaogku S, Kaya B (2008) Genotoxicity testing of four benzyl derivatives in the Dro-
sophila wing spot test. Food Chem Toxicol 46: 1034–1441
Demir E, Kocaogku S, Kaya B (2010) Assessment of genotoxic effects of benzyl derivatives by the 
comet assay. Food Chem Toxicol 48: 1239–1242
Deuel Jr HJ, Alfin-Slater R, Weil CS, Smyth Jr HF (1954) Sorbic acid as a fungistatic agent for 
foods. I. Harmlessness of sorbic acid as a dietary component. Food Res 19: 1–12
ECHA (European Chemicals Agency) (2011) Annex VI report, proposal for harmonised classifi-
cation and labelling, benzoic acid, European Chemicals Agency, Helsinki, Finnland,   
http://echa.europa.eu/documents/10162/13626/clh_benzoic_acid_en.pdf
EFSA (European Food Safety Authority) (2012) Scientific opinion: Guidance on selected default 
values to be used by the EFSA scientific committee, scientific panels and units in the absence 
of actual measured data. EFSA J 10: 2579,   
http://www.efsa.europa.eu/de/efsajournal/doc/2579.pdf
Fall M, Haddouk H, Morin J-P, Forster R (2007) Mutagenicity of benzyl chloride in the Salmonel-
la/microsome mutagenesis assay depends on exposure conditions. Mutat Res 633: 13–20
Fanelli GM, Halliday SL (1963) Relative toxicity of chlortetracycline and sodium benzoate after 
oral administration to rats. Arch Int Pharmacodyn 114: 120–125
FDA (Food and Drug Administration) (1972) Teratologic evaluation of FDA 71-37 (Sodium Ben-
zoate). PB 221777, NTIS, Alexandria, VA, USA
FDA (1974) Summary of mutagenicity screening studies, host-mediated assay, cytogenetics, 
dominant lethal assay, contract FDA 71-268, compound FDA 71-37, sodium benzoate. PB 
245453, NTIS, Alexandria, VA, USA
Feldmann RJ, Maibach HI (1970) Absorption of some organic compounds through the skin in 
man. J Invest Dermatol 54: 399–404
Forsbeck M, Skog E (1977) Immediate reactions to patch tests with balsam of Peru. Contact 
Dermatitis 3: 201–205
Frantz SW, Dittenber DA, Eisenbrandt DL, Watanabe PG (1990) Evaluation of a flow-through in 
vitro skin penetration chamber method using acetone-deposited organic solids. J Toxicol Cut 
Ocular Toxicol 9: 277–299
Franz TJ (1975) Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol 64: 
190–195
Frosch PJ, Kligman AM (1976) The chamber-scarification test for irritancy. Contact Dermatitis 
2: 314–324
Fujitani T (1993) Short-term effect of sodium benzoate in F344 rats and B6C3F1 mice. Toxicol 
Lett 69: 171–179
Gad SC, Dunn BJ, Dobbs DW, Reilly C, Walsh RD (1986) Development and validation of an al-
ternative dermal sensitization test: The mouse ear swelling test (MEST). Toxicol Appl Phar-
macol 84: 93–114
Geier J, Uter W, Lessmann H, Schnuch A (2003 a) The positivity ratio – another parameter to 
assess the diagnostic quality of a patch test preparation. Contact Dermatitis 48: 280–282
Geier J, Uter W, Pirker C, Frosch PJ (2003 b) Patch testing with the irritant sodium lauryl sulfate 
(SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. Con-
tact Dermatitis 48: 99–107
Gerberick GF, House RV, Fletcher ER, Ryan CA (1992) Examination of the local lymph node as-
say for use in contact sensitization risk assessment. Fundam Appl Toxicol 19: 438-445
Gollhausen R, Kligman AM (1985) Human assay for identifying substances which induce non-al-
lergic contact urticaria: the NICU-test. Contact Dermatitis 13: 98–106
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
Benzoic acid and alkali benzoates 1823
Goossens A, Claes L, Drieghe J, Put E (1998) Antimicrobials: preservatives, antiseptics and dis-
infectants. Contact Dermatitis 39: 133–134
Grant WM, Schuman JS (1993) Toxicology of the eye, Charles C Thomas Ltd, Springfield, Illi-
nois, USA, 215
Hausen BM (2001) Contact allergy to Balsam of Peru. II. Patch test results in 102 patients. Am J 
Contact Dermatitis 12: 93–102
Hotchkiss SAM, Hewitt P, Caldwell J, Chen WL, Rowe RR (1992) Percutaneous absorption of 
nicotinic acid, phenol, benzoic acid and triclopyr butoxyethyl ester through rat and human 
skin in vitro: further validation of an in vitro model by comparison with in vivo data. Food 
Chem Toxicol 30: 891–899
Hunziker N, Feldmann RJ, Maibach HI (1978) Animal models of percutaneous penetration: 
Comparison between Mexican hairless dogs and man. Dermatologica 156: 79–88
Ishidate Jr M (1988) Data book of chromosomal aberration test in vitro. Amsterdam Elsevier, 
9–20 and 23, 40, 373
Ishidate Jr M, Odashima S (1977) Chromosome tests with 134 compounds on Chinese hamster 
cells in vitro – a screening for chemical carcinogens. Mutat Res 48: 337–354
Ishidate M, Yoshikawa K (1980) Chromosome aberration tests with Chinese hamster cells in vi-
tro with and without metabolic activation – a comparative study on mutagens and carcino-
gens. Arch Toxicol, Suppl 4: 41–44
Ishidate Jr M, Sofuni T, Yoshikawa K, Hayashi M, Nohmi T, Sawada M, Matsuoka A (1984) Pri-
mary mutagenicity screening of food additives currently used in Japan. Food Chem Toxicol 
22: 623–636
Ishidate Jr M, Harnois MC, Sofuni T (1988) A comparative analysis of data on the clastogenicity 
of 951 chemical substances tested in mammalian cell cultures. Mutat Res 195: 151–213
Ishizaki M, Ueno S (1989) The DNA-damaging activity of natural and synthetic food additives 
(V). J Food Hyg Soc Jpn 30: 447–451
Jappe U, Schnuch A, Uter W (2003) Frequency of sensitization to antimicrobials in patients with 
atopic eczema compared with non-atopic individuals: analysis of multicentre surveillance 
data, 1995–1999. Br J Dermatol 149: 87–93
Juhlin L (1981) Recurrent urticaria: clinical investigations of 330 patients. Br J Dermatol 104: 
369–381
Kaboglu A, Aktac T (2002) A study of the effects of sodium benzoate on the mouse liver. Biologia 
57: 375–382
Kanerva L, Rantanen T, Aalto-Korte K, Estlander T, Hannuksela M, Harvima RJ, Hasan T, 
 Horsmanheimo M, Jolanki R, Kalimo K, Lahti A, Lammintausta K, Lauerma A, Niinimäki A, 
Turjanmaa K, Vuorela AM (2001) A multicenter study of patch test reactions with dental 
screening series. Am J Contact Dermatitis 12: 83–87
Kawachi T, Komatsu T, Kada T, Ishidate M, Sasaki M, Sugiyama T, Tazima Y (1980) Results of 
recent studies on the relevance of various short-term screening tests in Japan. The predictive 
value of short-term screening tests in carcinogenicity evaluation. in: Williams GM, Kroes R, 
Waaijers HW, van de Poll KW (Eds), Elsevier/North-Holland Biomedical Press, Amsterdam, 
253–267
Kieckebusch W, Lang K (1960) Die Verträglichkeit der Benzoesäure im chronischen Fütterungs-
versuch (The tolerability of benzoic acid in chronic feeding experiments) (German). 
Arzneimittelforschung 10: 1001–1003
Kimmel CA, Wilson JG, Schumacher HJ (1971) Studies on metabolism and identification of the 





produktionstitel: BAT Value Documentations 2017
<kurztitel>: Addendum to Methyl bromide 
DOI_Umbruchversand: xxxx
The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 4
Kreis H, Frese K, Wilmes G (1967) Physiologische und morphologische Veränderungen an Rat-
ten nach peroraler Verabreichung von Benzoesäure (Physiological and histological changes in 
rats fed benzoic acid) (German). Food Cosmet Toxicol 5: 505–511
Lahti A (1980) Non-immunologic contact urticaria. Acta Derm Venereol 60, Suppl 91: 1–49
Lahti A (1987) Terfenadine does not inhibit non-immunologic contact urticaria. Contact Der-
matitis 16: 220–223
Lahti A, Maibach HI (1984) An animal model for nonimmunologic contact urticaria. Toxicol 
Appl Pharmacol 76: 219–224
Lahti A, Maibach HI (1985) Species specificity of nonimmunologic contact urticaria: Guinea pig, 
rat, and mouse. J Am Acad Dermatol 13: 66–69
Lahti A, Noponen SL (1998) Propylene glycol in an isopropanol vehicle enhances immediate ir-
ritant reactions to benzoic acid. Contact Dermatitis 39: 150–151
Lahti A, Oikarinen A, Viinikka L, Ylikorkala O, Hannuksela M (1983) Prostaglandins in contact 
urticaria induced by benzoic acid. Acta Derm Venereol 63: 425–427
Lahti A, Väänänen A, Kokkonen EL, Hannuksela M (1987) Acetylsalicylic acid inhibits non-im-
munologic contact urticaria. Contact Dermatitis 16: 133–135
Lahti A, Poutainen AM, Hannuksela M (1993) Alcohol vehicles in tests for non-immunologic 
immediate contact reactions. Contact Dermatitis 29: 22–25
Lahti A, Pylvänen V, Hannuksela M (1995) Immediate irritant reactions to benzoic acid are en-
hanced in washed skin areas. Contact Dermatitis 33: 177–182
Lammintausta K, Maibach HI, Wilson D (1988) Mechanisms of subjective (sensory) irritation. 
Propensity to non-immunologic contact urticaria and objective irritation in stingers. Derm 
Beruf Umwelt 36: 45–49
Larmi E (1989) Systemic effect of ultraviolet irradiation on non-immunologic immediate contact 
reactions to benzoic acid and methyl nicotinate. Acta Derm Venereol 69: 296–301
Larmi E, Lahti A, Hannuksela M (1988) Effects of sorbitan sesquioleate on non-immunologic 
immediate contact reactions to benzoic acid. Contact Dermatitis 19: 368–371
Larmi E, Lahti A, Hannuksela M (1989 a) Effects of infra-red and neodymium yttrium alumini-
um garnet laser irradiation on non-immunologic immediate contact reactions to benzoic acid 
and methyl nicotinate. Derm Beruf Umwelt 37: 210–214
Larmi E, Lahti A, Hannuksela M (1989 b) Immediate contact reactions to benzoic acid and the 
sodium salt of pyrrolidone carboxylic acid. Contact Dermatitis 20: 38–40
Lewis MA, Lamey PJ, Forsyth A, Gall J (1989) Recurrent erythema multiforme: a possible role of 
foodstuffs. Br Dent J 166: 371–373
Leyden JJ, Kligman AM (1977) Contact sensitization to benzoyl peroxide. Contact Dermatitis 3: 
273–275
MacPherson SE, Barton CN, Bronaugh RL (1996) Use of in vitro skin penetration data and a 
physiologically based model to predict in vivo blood levels of benzoic acid. Toxicol Appl Phar-
macol 140: 436–443
Malanin G, Kalimo K (1989) The results of skin testing with food additives and the effect of an 
elimination diet in chronic and recurrent urticaria and recurrent angioedema. Clin Exp Aller-
gy 19: 539–543
Marquardt P (1960) Zur Verträglichkeit der Benzoesäure (On the tolerability of benzoic acid) 
(German) (abstract). Arzneimittelforschung 10: 1033
Marriott M, Holmes J, Peters L, Cooper K, Rowson M, Basketter DA (2005) The complex prob-
lem of sensitive skin. Contact Dermatitis 53: 93-99
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
Benzoic acid and alkali benzoates 1825
McKim JM, Jr., Keller DJ, III, Gorski JR (2010) A new in vitro method for identifying chemical 
sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human 
skin cells. Cutan Ocul Toxicol 29: 171–192
Meding B, Wrangsjö K, Brisman J, Järvholm B (2003) Hand eczema in 45 bakers – a clinical 
study. Contact Dermatitis 48: 7–11
Meynadier JM, Meynadier J, Colmas A, Castelain P-Y, Ducombs G, Chabeau G, Lacroix M, 
 Martin P, Ngangu Z (1982) Allergie aux conservateurs (Allergy to preservatives) (French). 
Ann Dermatol Venereol 109: 1017–1023
Michils A, Vandermoten G, Duchateau J, Yernault JC (1991) Anaphylaxis with sodium benzoate. 
Lancet 337: 1424–1425
Milvy P, Garro AJ (1976) Mutagenic activity of styrene oxide (1,2-epoxyethylbenzene), a pre-
sumed styrene metabolite. Mutat Res 40: 15–18
Minor JL, Becker BA (1971) A comparison of the teratogenic properties of sodium salicylate, 
sodium benzoate, and phenol (abstract). Toxicol Appl Pharmacol 19: 373
Monsanto (1981 a) Primary eye irritation of benzoic acid, U.S.P. to rabbits. in: Monsanto Com-
pany (1992) Initial submission: letter from Monsanto Co to USEPA regarding benzoic acid 
with attachments and cover letter dated 072392. OTS 0538627, NTIS, Alexandria, VA, USA, 
18–24
Monsanto (1981 b) Primary skin irritation of benzoic acid, U.S.P. to rabbits. in: Monsanto Com-
pany (1992) Initial submission: letter from Monsanto Co to USEPA regarding benzoic acid 
with attachments and cover letter dated 072392. OTS 0538627, NTIS, Alexandria, VA, USA, 
25–30
Monsanto (1981 c) Acute oral toxicity of benzoic acid, U.S.P. to rats. in: Monsanto Company 
(1992) Initial submission: letter from Monsanto Co to USEPA regarding benzoic acid with 
attachments and cover letter dated 072392. OTS 0538627, NTIS, Alexandria, VA, USA, 4–12
Monsanto (1981 d) Acute dermal toxicity of benzoic acid, U.S.P. to rabbits. in: Monsanto Com-
pany (1992) Initial submission: letter from Monsanto Co to USEPA regarding benzoic acid 
with attachments and cover letter dated 072392. OTS 0538627, NTIS, Alexandria, VA, USA, 
13–17
Monsanto (1983) Primary eye irritation of benzoic acid to rabbits. in: Monsanto Company 
(1992) Initial submission: primary eye irritation of benzoic acid to rabbits with cover letter 
dated 082892. OTS 0546102, NTIS, Alexandria, VA, USA, 4–19
Moon KC, Wester RC, Maibach HI (1990) Diseased skin models in the hairless guinea pig: in 
vivo percutaneous absorption. Dermatologia 180: 8–12
Mowafy AR, Darwish A-MH, El-Kholy SA, Abdel-Mohsen SH (2001) Effect of food preserva-
tives on mother rats and survival of their offspring. J Egypt Public Health Assoc 76: 281–295
Mpountoukas P, Vantarakis A, Sivridis E, Lialiaris T (2008) Cytogenetic study in cultured human 
lymphocytes treated with three commonly used preservatives. Food Chem Toxicol 46: 2390–
2393
Munoz FJ, Bellido J, Moyano JC, Alvarez M, Fonseca JL (1996) Perioral contact urticaria from 
sodium benzoate in a toothpaste. Contact Dermatitis 35: 51
Nair B (2001) Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium 
benzoate. Int J Toxicol 20, Suppl 3: 23–50
Nathan D, Sakr A, Lichtin JL, Bronaugh RL (1990) In vitro skin absorption and metabolism of 






produktionstitel: BAT Value Documentations 2017
<kurztitel>: Addendum to Methyl bromide 
DOI_Umbruchversand: xxxx
The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 4
Natsch A, Emter R (2008) Skin sensitizers induce antioxidant response element dependent 
genes: Application to the in vitro testing of the sensitization potential of chemicals. Toxicol 
Sci 102: 110–119
Natsch A, Haupt T (2013) Utility of rat liver S9 fractions to study skin-sensitizing prohaptens in 
a modified KeratinoSens assay. Toxicol Sci 135: 356–368
Nesslany F, Marzin D (1999) A micromethod for the in vitro micronucleus assay. Mutagenesis 
14: 403–410
Nethercott JR, Lawrence MJ, Roy AM, Gibson BL (1984) Airborne contact urticaria due to sodi-
um benzoate in a pharmaceutical manufacturing plant. J Occup Med 26: 734–736
Nettis E, Colanardi MC, Ferrannini A, Tursi A (2004) Sodium benzoate-induced repeated epi-
sodes of acute urticaria/angio-oedema: randomized controlled trial. Br J Dermatol 151: 898–
902
Nielsen JB, Nielsen F (2006) Topical use of tea tree oil reduces the dermal absorption of benzoic 
acid and methiocarb. Arch Dermatol Res 297: 395–402
Nielsen JB, Sørensen JA (2012) Glove material, reservoir formation, and dose affect glove perme-
ation and subsequent skin penetration. Sci Total Environ 417–418: 87–91
Nielsen JB, Sørensen JA, Nielsen F (2009) The Usual Suspects – Influence of Physicochemical 
Properties on Lag Time, Skin Deposition, and Percutaneous Penetration of Nine Model Com-
pounds. J Toxicol Environ Health A 72: 315–323
NLM (National Library of Medicine) (2014) Benzoic acid. Chemical Carcinogenesis Research 
Information System (CCRIS),   
http://toxnet.nlm.nih.gov/newtoxnet/ccris.htm
NLM (2016) Benzoic acid. Hazardous Substances Data Bank,   
http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB
Nonaka M (1989) DNA repair tests on food additives (abstract). Environ Mol Mutagen 14, Suppl 
15: 143
Noorafshan A, Erfanizadeh M, Karbalay-Doust S (2014) Sodium benzoate, a food preservative, 
induces anxiety and motor impairment in rats. Neurosciences 19: 24–28
OECD (Organisation of Economic Co-operation and Development) (2004) Benzoates, OECD 
SIDS Initial Assessment Report, UNEP (United Nations Environment Programme), Geneva,  
http://www.inchem.org/documents/sids/sids/benzoates.pdf
Onodera H, Ogiu T, Matsuoka C, Furuta K, Takeuchi M, Oono Y, Kubota T, Miyahara M, 
 Maekawa A, Odashima S (1978) Studies on effects of sodium benzoate on fetuses and off-
spring of Wistar rats. Eisei Shikenjo Hokoku 96: 47–54
Opdyke DLJ (1979) Monographs on fragrance raw materials. Benzoic acid. Food Cosmet Toxicol 
17: 715–722
Pacor ML, Lorenzo G Di, Martinelli N, Mansueto P, Rini GB, Corrocher R (2004) Monosodium 
benzoate hypersensitivity in subjects with persistent rhinitis. Allergy 59: 192–197
Petrus M, Bonaz S, Causse E, Rhabbour M, Moulie N, Netter JC, Bildstein G (1996) Asthme et 
intolérance aux benzoates (Asthma and intolerance to benzoates) (French). Arch Pediatr 3: 
984–987
Pevny I, Rauscher E, Lechner W, Metz J (1981) Exzessive Allergie gegen Benzoesäure mit ana-
phylaktischem Schock nach Expositionstest (Excessive allergy due to benzoic acid followed by 
anaphylactic shock) (German). Derm Beruf Umwelt 29: 123–130
Rademaker M, Forsyth A (1989) Contact dermatitis in children. Contact Dermatitis 20: 104–107
Reifenrath WG, Hawkins GS, Kurtz MS (1991) Percutaneous penetration and skin retention of 
topically applied compounds: an in vitro-in vivo study. J Pharm Sci 80: 526–532
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA
Benzoic acid and alkali benzoates 1827
Rosenhall L, Zetterström O (1975) Asthmatic patients with hypersensitivity to aspirin, benzoic 
acid and tartrazine. Tubercle 56: 219
Roskos KV, Maibach HI, Guy RH (1989) The effect of aging on percutaneous absorption in man. 
J Pharmacokinet Biopharm 17: 617–630
Rougier A, Dupuis D, Lotte C, Roguet R, Schaefer H (1983) In vivo correlation between stratum 
corneum reservoir function and percutaneous absorption. J Invest Dermatol 81: 275–278
van de Sandt JJM, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S, Korinth G, 
 Larese F, Limassett JC, Maas WJM, Montomoli L, Nielsen JB, Payan J-P, Robinson E, Sartorel-
li P, Schaller KH, Wilkinson SC, Williams FM (2004) In vitro predictions of skin absorption of 
caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul Toxicol Phar-
macol 39: 271–281
Sasaki YF, Kawaguchi S, Kamaya A, Ohshita M, Kabasawa K, Iwama K, Taniguchi K, Tsuda S 
(2002) The comet assay with 8 mouse organs: results with 39 currently used food additives. 
Mutat Res 519: 103–119
Schnuch A, Geier J, Uter W, Frosch PJ (1998) Patch testing with preservatives, antimicrobials 
and industrial biocides. Results from a multicenter study (IVDK). Br J Dermatol 138: 467–476
Schnuch A, Uter W, Lessmann H, Geier J (2008) Kontaktallergien gegen Konservierungsmittel. 
Ergebnisse des Informationsverbundes Dermatologischer Kliniken (IVDK) 1996 bis 2007 
(Contact allergy to preservatives. Results of the Information Network of Departments of Der-
matology (IVDK) 1996–2007) (German). Allergo J 17: 631–638
Schnuch A, Lessmann H, Geier J, Uter W (2011) Contact allergy to preservatives. Analysis of 
IVDK data 1996 - 2009. Br J Dermatol 164: 1316–1325
Shtenberg AJ, Ignatev AD (1970) Toxicological evaluation of some combinations of food preser-
vatives. Food Cosmet Toxicol 8: 369–380
Sodemoto Y, Enomoto M (1980) Report of carcinogenesis bioassay of sodium benzoate in rats: 
Absence of carcinogenicity of sodium benzoate in rats. J Environ Pathol Toxicol 4: 87–95
SRC (Syracuse Research Corporation) (2014 a) Benzoic acid, PhysProp database,   
http://esc.srcinc.com/fatepointer/search.asp
SRC (2014 b) Benzoic acid, sodium salt, PhysProp database,   
http://esc.srcinc.com/fatepointer/search.asp
Supramaniam G, Warner JO (1986) Artificial food additives intolerance in patients with an-
gioedema and urticaria. Lancet 328: 907–909
The Personal Care Products Council (2010) A 4-week inhalation toxicity study of aerosolized 
benzyl alcohol and benzoic acid in Sprague-Dawley rats. Study number WIL-703002, The 
Personal Care Products Council, Washington, D.C., USA, unpublished report
Torgerson RR, Davis MDP, Bruce AJ, Farmer SA, Rogers RS (2007) Contact allergy in oral dis-
ease. J Am Acad Dermatol 57: 315–321
Toth B (1984) Lack of tumorigenicity of sodium benzoate in mice. Fundam Appl Toxicol 4: 494–
496
Velsicol Chemical Company (1981) Four week subacute inhalation study of benzoic acid in rats. 
International Research and Development Corporation, Project No 163-676, Velsicol Chemi-
cal Company, Chicago, IL, USA, unpublished report
Vilaplana J, Romaguera C (2003) Fixed drug eruption from sodium benzoate. Contact Dermatitis 
49: 290–291
Wallengren J, Larsson B (2001) Nitric oxide participates in prick test and irritant patch test reac-
tions in human skin. Arch Dermatol Res 293: 121–125
Wester RC, Maibach HI (1976) Relationship of topical dose and percutaneous absorption in 





produktionstitel: BAT Value Documentations 2017
<kurztitel>: Addendum to Methyl bromide 
DOI_Umbruchversand: xxxx
The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 4
WHO (World Health Organization) (2000) Benzoic acid and sodium benzoate. IPCS – Concise 
international chemical assessment document 26, WHO, Geneva, Switzerland,   
http://www.who.int/ipcs/publications/cicad/cicad26_rev_1.pdf?ua=1
Xing W, Zhang Z (1990) A comparison of SCE test in human lymphocytes and vicia faba: a hope-
ful technique using plants to detect mutagens and carcinogens. Mutat Res 241: 109–113
Yilmaz S, Ünal F, Yüzbasioglu D (2009) The in vitro genotoxicity of benzoic acid in human pe-
ripheral blood lymphocytes. Cytotechnology 60: 55–61
Yilmaz S, Ünal F, Yüzbasioglu D, Celik M (2014) DNA damage in human lymphocytes exposed 
to four food additives in vitro. Toxicol Ind Health 30: 926–937
Ylipieti S, Lahti A (1989) Effect of the vehicle on non-immunologic immediate contact reactions. 
Contact Dermatitis 21: 105–106
Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K (1988) Salmonella mutagenicity 
tests: IV. Results from the testing of 300 chemicals. Environ Mol Mutagen 11, Suppl 12: 1–158
Zengin N, Yüsbasioglu D, Ünal F, Yilmaz S, Aksoy H (2011) The evaluation of the genotoxicity of 
two food preservatives: Sodium benzoate and potassium benzoate. Food Chem Toxicol 49: 
763–769
completed February 24, 2016
